The new injection of GileAd HIV prevention obtains the approval of the FDA
The FDA authorizes the AI tool to predict the risk of breast cancer
The principal medical analyst, Dr. Marc Siegel, discusses the progress of artificial intelligence aimed at predicting the future risk of an individual’s breast cancer and the risks increased to cannabis health as users are aging.
NEWYou can now listen to Fox News articles!
The Food and Drug Administration of the United States (FDA) has approved a new shot twice a year – the first and the only one in its kind – to Prevent HIVThe creator of the drug, Gilead Sciences, announced on Wednesday.
Sold under the name of Yeztugo, the HIV-1 injectable company capside inhibitor (Lenacapavir) reduces the risk of HIV sexually acquired in adults and adolescents.
“This is a historic day in the fight of several decades against HIV,” said Daniel O’Day, Chairman and CEO of Gilead Sciences, based in California, in a press release.
Alzheimer’s disease could be avoided by an antiviral drug already on the market
The drug, which should only be administered twice a year, has shown “remarkable results in clinical studies“As Gilead claims, he could transform HIV prevention.
The US Food and Drug Administration approved a new shot twice a year, Yeztugo, to prevent HIV, the creator of the drug announced on Wednesday. (Gilead Sciences via AP)
The drug is given as an injectable under the skin that the body then absorbs slowly. Individuals must pass a negative test of HIV-1 before starting treatment.
Click here to obtain the Fox News app
In the major trials of last year, the drug was not only effective by almost 100% in its HIV prevention, but turned out to be over oral drugs once a day like Truvada, another Gilead medication.
The drug is given as an injectable under the skin that the body then absorbs slowly. Individuals must pass a negative test of HIV-1 before starting treatment. (AP photo / Nardus Engelbrecht)
The Revue Science has named Lenacapavir its “breakthrough of the year” of 2024.
Click here to register for our Health Newsletter
Lenacapavir uses a several -step approach that distinguishes it from others Antiviral drugs.
Sold under the name of Yeztugo, the HIV-1 injectable company capside inhibitor (Lenacapavir) reduces the risk of HIV sexually acquired in adults and adolescents. (istock)
“While most antivirals act on a single stage of viral replication, Lenacapavir is designed to inhibit HIV in several stages of its life cycle,” said Gilead’s press release.
For more health items, visit www.foxnews.com/health
“Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help put an end to the HIV epidemic,” O’Day said in the press release.
According to the company.
